Clarus Therapeutics to Report First Quarter 2022 Financial and Operating Results
12 Mayo 2022 - 8:05AM
Clarus Therapeutics Holdings, Inc. (“Clarus”) (Nasdaq:CRXT), a
pharmaceutical company dedicated to providing solutions to unmet
medical needs by advancing androgen and metabolic therapies for men
and women, today announced it will release its first quarter 2022
financial and operating results on Monday, May 16, 2022, after the
market closes.
Clarus will host a conference call on Monday, May
16, 2022, at 5:15 p.m. ET to discuss the results. The dial-in
numbers are (844) 249-2007 for domestic callers and (224) 619-3902
for international callers. The conference ID number is 7677008. A
live webcast and replay of the conference call will be accessible
through the Investors section of Clarus Therapeutics’ website
at Investors.ClarusTherapeutics.com.
About Clarus Therapeutics Holdings,
Inc.Clarus Therapeutics Holdings, Inc. is a pharmaceutical
company with expertise in developing androgen and metabolic
therapies for men and women – including potential therapies for
orphan indications. Clarus Therapeutics’ first commercial product
is JATENZO® (testosterone undecanoate). For more information, visit
www.clarustherapeutics.com and www.jatenzo.com. Follow us on
Twitter (@Clarus_Thera) and LinkedIn (Clarus Therapeutics).
JATENZO® is a registered trademark of Clarus
Therapeutics Holdings, Inc.
Clarus Investor Relations
Contact:
Kara StancellVice President, Investor Relations
& Corporate Communicationskstancell@clarustherapeutics.com(847)
562-4300 x 206
Clarus Therapeutics (NASDAQ:CRXT)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Clarus Therapeutics (NASDAQ:CRXT)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about Clarus Therapeutics Holdings Inc (NASDAQ): 0 recent articles
Más de Artículos de Noticias